Seres Therapeutics, Inc. (MCRB) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
MCRB Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Seres Therapeutics, Inc. (MCRB) trades at a price-to-earnings ratio of 12.1x, with a stock price of $7.72 and trailing twelve-month earnings per share of $-4.89.
The current P/E is 55% below its 5-year average of 27.0x. Over the past five years, MCRB's P/E has ranged from a low of 22.5x to a high of 31.5x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, MCRB trades at a 46% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, MCRB trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MCRB DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
MCRB P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 9.9Lowest | - | +68%Best | |
| $15B | 32.0 | 13.69Best | +42% | |
| $151B | 19.5 | - | -4% | |
| $536B | 38.4 | - | -58% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
MCRB Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $14.88 | $0.66 | 22.5x | -17% |
| FY2025 Q3 | $19.24 | $0.61 | 31.5x | +17% |
Average P/E for displayed period: 27.0x
See MCRB's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MCRB Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MCRB vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonMCRB — Frequently Asked Questions
Quick answers to the most common questions about buying MCRB stock.
Is MCRB stock overvalued or undervalued?
MCRB trades at 12.1x P/E, below its 5-year average of 27.0x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does MCRB's valuation compare to peers?
Seres Therapeutics, Inc. P/E of 12.1x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is MCRB's PEG ratio?
MCRB PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.